ChanTest Corporation
14656 Neo Parkway
Cleveland
Ohio
44128
United States
Tel: 216-332-1665
Fax: 216-332-1706
Website: http://www.chantest.com/
Email: info@chantest.com
32 articles about ChanTest Corporation
-
ChanTest Corporation CEO Named Distinguished Service Award Recipient by the Safety Pharmacology Society
7/24/2013
-
BioFocus DPI Expands Ion Channel Offering Through Agreement With ChanTest Corporation
2/6/2013
-
ChanTest Corporation Goes Beyond GLP to Become First Ion Channel and GPCR CRO With Cgmp Testing Capability
1/14/2013
-
ChanTest Corporation Announces Drug Discovery Services Using the Enamine Ltd. 3D Compound Library
10/16/2012
-
ChanTest Corporation Awarded $1 Million Grant for Predictive Assays Using Stem Cell-Derived Human Cardiomyocytes
9/18/2012
-
ChanTest Corporation Hires Chris Mathes as Chief Commercial Officer
8/17/2012
-
ChanTest Corporation Sponsors Great Strides Walk for Cystic Fibrosis
5/8/2012
-
Roche, ChanTest Corporation Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
12/5/2011
-
ChanTest Corporation Signs Research Collaboration Agreement with The FDA
6/9/2011
-
ChanTest Corporation First To Offer New High Throughput Electrophysiology Platform Validated for Both VGICs and LGICs
4/6/2011
-
Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement
3/24/2011
-
ChanTest Corporation and Molecular Devices Ltd Sign Cell Line Distribution Agreement
3/24/2011
-
D. Thomas Oakley Named President and CEO of ChanTest Corporation
9/9/2010
-
Emir Duzic to Head GPCR Assay Services for ChanTest Corporation
7/15/2010
-
ChanTest Corporation Release: Drug Safety Executive Council Presents: Improved Strategies for Pre-clinical Cardiac Testing
6/21/2010
-
ChanTest Corporation CEO to Speak on New Pre-Clinical Assays for Predicting Cardiotoxicity at Society of Toxicology Annual Meeting
3/4/2010
-
ChanTest Corporation To Hold Free Webinar on Stem Cell-Derived Human Cardiomyocyte Assays in Cardiac Risk Evaluation
2/4/2010
-
Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
11/12/2009
-
MaxCyte, Inc. Webinar with Case Studies from ChanTest, Inc.: Improving Large Scale GPCR and Ion Channel Assays
6/15/2009
-
ChanTest, Inc. Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program
5/6/2009